MCID: LKM002
MIFTS: 72

Leukemia

Categories: Blood diseases, Bone diseases, Cancer diseases, Immune diseases

Aliases & Classifications for Leukemia

Summaries for Leukemia

MedlinePlus : 44 Leukemia is cancer of the white blood cells. White blood cells help your body fight infection. Your blood cells form in your bone marrow. In leukemia, the bone marrow produces abnormal white blood cells. These cells crowd out the healthy blood cells, making it hard for blood to do its work. There are different types of leukemia, including Acute lymphocytic leukemia Acute myeloid leukemia Chronic lymphocytic leukemia Chronic myeloid leukemia Leukemia can develop quickly or slowly. Chronic leukemia grows slowly. In acute leukemia, the cells are very abnormal and their number increases rapidly. Adults can get either type; children with leukemia most often have an acute type. Some leukemias can often be cured. Other types are hard to cure, but you can often control them. Treatments may include chemotherapy, radiation and stem cell transplantation. Even if symptoms disappear, you might need therapy to prevent a relapse. NIH: National Cancer Institute

MalaCards based summary : Leukemia is related to acute leukemia and childhood leukemia, and has symptoms including angina pectoris, edema and chest pain. An important gene associated with Leukemia is MIR27A (MicroRNA 27a), and among its related pathways/superpathways are Endometrial cancer and Pathways in cancer. The drugs Arranon and Arzerra have been mentioned in the context of this disorder. Affiliated tissues include myeloid, t cells and b cells, and related phenotypes are Increased HDAC inhibitor resistance and cellular

Disease Ontology : 12 A cancer that affects the blood or bone marrow characterized by an abnormal proliferation of blood cells.

Wikipedia : 77 Leukemia, also spelled leukaemia, is a group of blood cancers that usually begin in the bone marrow and... more...

Related Diseases for Leukemia

Diseases in the Leukemia family:

Acute Leukemia Chronic Leukemia
Subacute Leukemia

Diseases related to Leukemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1693)
# Related Disease Score Top Affiliating Genes
1 acute leukemia 34.5 CEBPA ETV6 FLT3 RUNX1
2 childhood leukemia 34.5 ABL1 ETV6 PBX1 RUNX1
3 leukemia, acute lymphoblastic 34.4 ABL1 BCR ETV6 FLT3 MIR27A RUNX1
4 acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22) 34.4 ETV6 FLT3 RUNX1
5 acute myeloblastic leukemia without maturation 34.3 FLT3 NPM1
6 acute myeloblastic leukemia with maturation 34.3 FLT3 NPM1
7 chronic myelomonocytic leukemia 34.3 ETV6 FLT3 RUNX1
8 cytogenetically normal acute myeloid leukemia 34.3 CEBPA FLT3 NPM1
9 core binding factor acute myeloid leukemia 34.3 CEBPA FLT3 RUNX1
10 myeloid leukemia 34.2 ABL1 BCR CEBPA ETV6 FLT3 LIF
11 leukemia, chronic myeloid 34.2 ABL1 BCR ETV6 FLT3 HOTAIR RUNX1
12 b-cell childhood acute lymphoblastic leukemia 34.1 ETV6 RUNX1
13 lymphoid leukemia 34.0 ETV6 FLT3
14 lymphocytic leukemia 34.0 BCR ETV6 HOTAIR RUNX1
15 leukemia, acute lymphoblastic 3 33.9 ABL1 BCR ETV6 FLT3 PBX1 RUNX1
16 acute lymphocytic leukemia 33.8 BCR CDKN2B-AS1 ETV6 RUNX1
17 b-cell adult acute lymphocytic leukemia 33.8 ABL1 PBX1
18 aleukemic leukemia cutis 33.8 FLT3 NPM1 RUNX1
19 precursor t-cell acute lymphoblastic leukemia 33.8 ABL1 BCR ETV6 FLT3 TCL1A
20 acute promyelocytic leukemia 33.8 CEBPA FLT3 HOTAIRM1 NEAT1 NPM1 PML
21 acute myeloid leukemia with t(8;21)(q22;q22) translocation 33.7 CEBPA FLT3 RUNX1
22 philadelphia-negative chronic myeloid leukemia 33.7 ABL1 BCR
23 platelet disorder, familial, with associated myeloid malignancy 33.3 ETV6 RUNX1
24 myelodysplastic syndrome 33.0 ABL1 CEBPA ETV6 FLT3 MLF1 NPM1
25 8p11 myeloproliferative syndrome 32.7 BCR FLT3 RUNX1
26 leukemia, acute myeloid 32.5 ABL1 BCR CDKN2B-AS1 CEBPA ETV6 FLT3
27 bone marrow cancer 31.0 ABL1 BCR ETV6 FLT3 RUNX1
28 kidney cancer 29.2 GAS5 HOTAIR MIR27A
29 thyroid cancer, nonmedullary, 1 28.8 GAS5 HOTAIR NEAT1
30 melanoma 28.8 CDKN2B-AS1 GAS5 HOTAIR HOTAIRM1 MIR27A
31 glioma 28.8 CDKN2B-AS1 GAS5 HOTAIR NEAT1
32 osteogenic sarcoma 28.6 CDKN2B-AS1 GAS5 HOTAIR NEAT1
33 thyroid cancer 28.6 CDKN2B-AS1 GAS5 HOTAIR MLF1 NEAT1
34 nasopharyngeal carcinoma 28.4 CDKN2B-AS1 GAS5 HOTAIR NEAT1
35 malignant glioma 28.3 CDKN2B-AS1 GAS5 HOTAIR NEAT1
36 oral squamous cell carcinoma 28.1 HOTAIR MIR27A NEAT1
37 leukemia, chronic lymphocytic 12.6
38 hairy cell leukemia 12.5
39 juvenile myelomonocytic leukemia 12.5
40 megakaryocytic leukemia 12.5
41 leukemia, acute monocytic 12.4
42 t-cell prolymphocytic leukemia 12.4
43 adult t-cell leukemia 12.4
44 acute lymphoblastic leukemia, childhood 12.4
45 acute monoblastic leukemia 12.4
46 prolymphocytic leukemia 12.4
47 pdgfrb-associated chronic eosinophilic leukemia 12.4
48 plasma cell leukemia 12.4
49 atypical chronic myeloid leukemia 12.3
50 chronic neutrophilic leukemia 12.3

Comorbidity relations with Leukemia via Phenotypic Disease Network (PDN):


Acute Cystitis Deficiency Anemia
Heart Disease Leukemia, Chronic Lymphocytic

Graphical network of the top 20 diseases related to Leukemia:



Diseases related to Leukemia

Symptoms & Phenotypes for Leukemia

UMLS symptoms related to Leukemia:


angina pectoris, edema, chest pain

GenomeRNAi Phenotypes related to Leukemia according to GeneCards Suite gene sharing:

27
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased HDAC inhibitor resistance GR00115-A-0 8.62 LIF LIFR

MGI Mouse Phenotypes related to Leukemia:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.22 ABL1 BCR CEBPA ETV6 FLT3 LIF
2 hematopoietic system MP:0005397 10.15 ABL1 BCR CEBPA ETV6 FLT3 LIF
3 growth/size/body region MP:0005378 10.14 ABL1 BCR CEBPA ETV6 FLT3 LIF
4 endocrine/exocrine gland MP:0005379 10.13 ABL1 CEBPA ETV6 FLT3 LIF LIFR
5 immune system MP:0005387 10.1 ABL1 BCR CEBPA ETV6 FLT3 LIF
6 embryo MP:0005380 10.06 ABL1 ETV6 LIF LIFR NPM1 PBX1
7 mortality/aging MP:0010768 9.93 ABL1 BCR CEBPA ETV6 FLT3 LIF
8 liver/biliary system MP:0005370 9.91 ABL1 BCR CEBPA LIF LIFR NPM1
9 neoplasm MP:0002006 9.5 CEBPA ETV6 FLT3 NPM1 PML RAF1
10 normal MP:0002873 9.23 ABL1 BCR CEBPA ETV6 PBX1 PML

Drugs & Therapeutics for Leukemia

FDA approved drugs:

(show all 27)
# Drug Name Active Ingredient(s) 19 Company Approval Date
1
Arranon 19 50 NELARABINE GlaxoSmithKline October 2005
2
Arzerra 19 50 OFATUMUMAB GlaxoSmithKline October 2009
3
Bexxar 19 50 TOSITUMOMAB; IODINE I 131 TOSITUMOMAB Corixa June 2003
4
Blincyto 19 50 BLINATUMOMAB Amgen December 2014
5
Bosulif 19 50 BOSUTINIB MONOHYDRATE Pfizer September 2012
6
Busulfex 19 50 BUSULFAN Orphan Medical February 1999
7
Campath 19 50 ALEMTUZUMAB Berlex Laboratories May 2001
8
Clolar 19 50 CLOFARABINE Genzyme December, 2004
9
Elitek 19 50 RASBURICASE sanofi-aventis October 2009
10
Elliotts B Solution 19 CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM SULFATE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE Orphan Medical October 1996
11
Erwinaze 19 50 asparaginase Erwinia chrysanthemi Eusa Pharma November of 2011
12
Gazyva 19 50 OBINUTUZUMAB Genentech October of 2013
13
Gleevec 19 50 IMATINIB MESYLATE Novartis May 2001
14
Iclusig 19 50 PONATINIB HYDROCHLORIDE Ariad Pharmaceuticals December 2012
15
Imbruvica 19 50 IBRUTINIB Pharmacyclics November of 2013/February 2014
16
Intron A 19 50 INTERFERON ALFA-2B Schering-Plough December 1997/ December 1995/ March 1997
17
Leukine 19 SARGRAMOSTIM Immunex on November 24, 1995/ November 1996
18
Marqibo 19 50 VINCRISTINE SULFATE Talon Therapeutics August 2012
19
Mylotarg 19 50 GEMTUZUMAB OZOGAMICIN Wyeth May 2000
20
Neupogen 19 50 FILGRASTIM Amgen Approval April 1998
21
Revlimid 19 50 LENALIDOMIDE Celgene June 2013
22
Sprycel 19 50 DASATINIB Bristol-Myers Squibb June 2006
23
Synribo 19 50 OMACETAXINE MEPESUCCINATE Teva Pharmaceutical October 2012
24
Tasigna 19 50 NILOTINIB HYDROCHLORIDE MONOHYDRATE Novartis October 2007
25
Treanda 19 50 BENDAMUSTINE HYDROCHLORIDE Cephalon October 2008
26
Trisenox 19 50 ARSENIC TRIOXIDE Cell Therapeutics September 2000
27
Zydelig 19 50 IDELALISIB Gilead July 2014

Drugs for Leukemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 1027)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Daunorubicin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 20830-81-3 30323
2
Mitoxantrone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 65271-80-9 4212
3
Cytarabine Approved, Experimental, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 147-94-4, 65-46-3 6253
4
Idarubicin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 58957-92-9 42890
5
Arsenic trioxide Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 1327-53-3 518740
6
Fludarabine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 75607-67-9, 21679-14-1 30751
7
Vidarabine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 24356-66-9 21704 32326
8
Pentostatin Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 53910-25-1 40926 439693
9
Adenosine Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 58-61-7 60961
10
rituximab Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 174722-31-7 10201696
11
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 6055-19-2, 50-18-0 2907
12
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 1177-87-3
13
leucovorin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 58-05-9 6006 143
14
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 50-02-2 5743
15
Dasatinib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 302962-49-8 3062316
16
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 53-03-2 5865
17
Methotrexate Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 1959-05-2, 59-05-2 126941
18
Vincristine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 2068-78-2, 57-22-7 5978
19
Mercaptopurine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 50-44-2 667490
20
Hydrocortisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-23-7 5754
21
Teniposide Approved Phase 4,Phase 3,Phase 2,Not Applicable 29767-20-2 34698
22
Hydrocortisone acetate Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-03-3
23
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-24-8 5755
24
Prednisolone phosphate Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 302-25-0
25
Sargramostim Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 123774-72-1, 83869-56-1
26
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 83-43-2 6741
27
Methylprednisolone hemisuccinate Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 2921-57-5
28
Lenograstim Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 135968-09-1
29
Pegaspargase Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 130167-69-0
30
Doxorubicin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 23214-92-8 31703
31
Decitabine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 2353-33-5 451668
32
Thioguanine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 154-42-7 2723601
33
Cladribine Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 4291-63-8 20279
34
Etoposide Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 33419-42-0 36462
35
Vindesine Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 59917-39-4, 53643-48-4 40839
36
Ifosfamide Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 3778-73-2 3690
37
Aprepitant Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 170729-80-3 151165 6918365
38
Fosaprepitant Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 172673-20-0 219090
39
Acitretin Approved Phase 4 55079-83-9, 69427-46-9 6437841
40
tannic acid Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1401-55-4
41
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 94-09-7, 1994-09-7 2337
42
Gemcitabine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 95058-81-4 60750
43
Cisplatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 15663-27-1 441203 84093 2767
44
Epirubicin Approved Phase 4,Phase 3,Phase 2 56420-45-2 41867
45
Chlorambucil Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 305-03-3 2708
46
Topotecan Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 123948-87-8, 119413-54-6 60700
47
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 22916-47-8 4189
48
Amphotericin B Approved, Investigational Phase 4,Phase 3,Phase 2 1397-89-3 14956 5280965
49
Amsacrine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 51264-14-3 2179
50
ofatumumab Approved Phase 4,Phase 3,Phase 2,Phase 1 679818-59-8 6918251

Interventional clinical trials:

(show top 50) (show all 6665)
# Name Status NCT ID Phase Drugs
1 AIDA2000 - Risk-Adapted Therapy for Patients With Acute Promyelocytic Leukemia Unknown status NCT00180128 Phase 4 all-trans retinoid acid;idarubicin;mitoxantrone;daunorubicin;cytarabine
2 Idarubicin at Different Dosages as Induction Therapy for Newly Diagnosed Acute Myeloid Leukaemia Unknown status NCT02277847 Phase 4 Idarubicin(8mg/m2) and cytosine arabinoside;Idarubicin(10mg/m2), cytosine arabinoside
3 Treatment Protocol for Relapsed Acute Promyelocytic Leukemia (APL) With Arsenic Unknown status NCT00196768 Phase 4 Arsenic trioxide;Trisenox
4 AML1-ETO Acute Myeloid Leukemia With Fludarabine and Cytarabine Chemotherapy Unknown status NCT02024308 Phase 4 Fludarabine;Cytarabine
5 Efficacy and Safety of Imatinib Mesylate as First-line Treatment for the Patients With Chronic Phase of Chronic Myeloid Leukemia Unknown status NCT02317159 Phase 4 Imatinib
6 Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia. Unknown status NCT00131313 Phase 4 Nipent, Cytoxan, Rituxan
7 Low-dose Chemotherapy Combine With Tyrosine Kinase Inhibitor to Treat ph+ Acute Lymphoblastic Leukemia Patients Unknown status NCT02690922 Phase 4 Dasatinib;prednisone;dexamethasone;methotrexate
8 Treatment Protocol of Children With Philadelphia Chromosome Negative High Risk Acute Lymphoblastic Leukemia Unknown status NCT01990807 Phase 4 Idarubicin(IDA)
9 The GD-2008 ALL Protocol for Childhood Acute Lymphoblastic Leukemia Unknown status NCT00846703 Phase 4 6-mercaptopurine, Methotrexate;6-mercaptopurine, Methotrexate, Vincristine, Dexamethasone
10 Treatment of High Risk Adult Acute Lymphoblastic Leukemia Unknown status NCT00853008 Phase 4 Vincristine;Daunorubicin;Prednisone;Mitoxantrone;Cytosine Arabinoside;Dexamethasone;Methotrexate (MTX);Cytarabine;ASP;Mercaptopurine;Teniposide;Hydrocortisone
11 German Multicenter Trial for Treatment of Elderly Patients With Newly Diagnosed Acute Lymphoblastic Leukemia Unknown status NCT00198978 Phase 4 Cyclophosphamide;Dexamethasone / Prednisolone;Cytarabine;Idarubicin;Granulocyte-Colony-Stimulating Factor;Mercaptopurine;Methotrexate;Rituximab;HDARAC;Vincristine;Depocyte;Asparaginase
12 Medical Research Council (MRC) Working Party on Leukaemia in Children UK National Acute Lymphoblastic Leukaemia (ALL) Trial: UKALL 2003 Unknown status NCT00222612 Phase 4 Standard childhood UK ALL protocol;Intensified treatment including Capizzi maintenance
13 3 Anthracyclines, 2 Types of Consolidation With Different ARA-C Doses and Maintenance in Adult Acute Myeloid Leukemia Unknown status NCT01587430 Phase 4 high dose ARA-C;standard dose ARA-C
14 Decitabine for Myelodysplastic Syndromes and Acute Myeloid Leukemia Before Allogeneic Hematopoietic Cell Transplantation Unknown status NCT01806116 Phase 4 decitabine
15 Combined Retinoic Acid,Arsenic Trioxide and Chemo for Newly-diagnosed APL Unknown status NCT01987297 Phase 4 ATRA+arsenic;ATRA+chemo
16 Malaysia-Singapore Acute Lymphoblastic Leukemia 2010 Study Unknown status NCT02894645 Phase 4 Prednisolone;Dexamethasone;L-Asparaginase;Vincristine;Methotrexate;Daunorubicin;Doxorubicin;Cyclophosphamide;Cytarabine;6-Mercaptopurine;Thioguanine;Fludarabine;Imatinib
17 Assessment Of Gh-Igf-1 Axis In Children With Chronic Myelogenous Leukemia (CML) In Remission Unknown status NCT01901666 Phase 4 Growth Hormone
18 German Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (07/2003) Unknown status NCT00198991 Phase 4 Cyclophosphamide;Dexamethasone;Vincristine;daunorubicin;Asparaginase;Methotrexate;Cytarabine;Mercaptopurine;G-CSF;Vindesine;VP16;Prednisolone;Adriamycin;Thioguanine;VM26;Idarubicin;Fludarabine;Cladribine
19 Compliance: Role Emerges for Success in Chronic Myelogenous Leukaemia (CML): Evaluation aND Optimisation Unknown status NCT01243489 Phase 4
20 Multicenter, PhaseⅣ, Open Label Trial of Nilotinib in Adult Patients Diagnosed Philadelphia Chromosome Positive(Ph+) Chronic Myeloid Leukemia in CP/AP Intolerant to Dasatinib Unknown status NCT02389920 Phase 4 Nilotinib
21 Poly(Ethylene Glycol)(PEG)-Asparaginase During Two Treatment Courses Unknown status NCT00192673 Phase 4 PEG-asparaginase
22 HD-Idarubicin/Etoposide Intensified Conditioning Regimen Allo-HSCT for Adult ALL Unknown status NCT01873807 Phase 4 IDA;CTX;VP-16
23 Efficacy of G-CSF-Priming in Elderly AML Patients Unknown status NCT00199147 Phase 4 Cytarabine;Etoposide;Idarubicin;G-CSF;Fludarabine
24 Interferon for the Intervention of Molecular Relapse in t (8; 21) AML After Allo-HSCT Unknown status NCT02027064 Phase 4 Interferon-alpha
25 Intensification Therapy of Mature B-ALL, Burkitt and Burkitt Like and Other High Grade Non-Hodgkin's Lymphoma in Adults Unknown status NCT00797810 Phase 4 Rituximab
26 Self-control Trial to Evaluate the Role of Aprepitant in the Prophylaxis of Post-lumbar-punture-headache (PLPH) Unknown status NCT02347878 Phase 4 Aprepitant
27 Low Grade Lymphoma Unknown status NCT01698866 Phase 4
28 Low-Dose (17.5 mg/Day) Acitretin: Comparable Efficacy Without the Side Effects? Unknown status NCT01228409 Phase 4 Acitretin 17.5 mg/day
29 Different Doses of Anti-thymocyte Globin to Treat Child Severe Aplastic Anemia Unknown status NCT01997372 Phase 4 ATG
30 Treatment Protocol of Child SAA With the Injection of Mesenchymal Stem Cells(Umbilical Cord Derived) Unknown status NCT02218437 Phase 4 MSC+ATG
31 CEOP/IVE/GDP Compared With CEOP as the First-line Therapy for Newly Diagnosed Adult Patients With PTCL Unknown status NCT02533700 Phase 4 CEOP/IVE/GDP chemotherapy regimen;CEOP chemotherapy regimen for 6 cycles
32 A Study of MabThera Added to Bendamustine or Chlorambucil in Patients With Chronic Lymphocytic Leukemia (MaBLe) Completed NCT01056510 Phase 4 bendamustine;chlorambucil;rituximab [MabThera/Rituxan]
33 Study to Evaluate Nilotinib in Chronic Myelogenous Leukemia (CML) Patients With SubOptimal Response Completed NCT01043874 Phase 4 Nilotinib
34 LAM07: Study to Analyze the Efficacy of a Risk Adapted Treatment Strategy, Including Gemtuzumab Ozogamicin (GO) During Consolidation, for Patients With Acute Myeloid Leukemia (AML) Completed NCT01041040 Phase 4 gemtuzumab
35 Treatment of the Acute Myeloblastic Leukaemia in Patients Over 65 Years Completed NCT00464217 Phase 4 ARA-C;Idarubicin;Leucomax
36 Treatment of Elderly Patients (>65 Years) With Acute Lymphoblastic Leukemia Completed NCT00199095 Phase 4 Adriamycin;Cyclophosphamide;Cytarabine;Dexamethasone;Idarubicin;Ifosfamide;Methotrexate;Mercaptopurine;VM26;Vincristine
37 Treatment of Relapsed Promyelocytic Leukemia With Arsenic Trioxide (ATO) Completed NCT00504764 Phase 4 Arsenic Trioxide;ATRA
38 Pulses of Vincristine and Dexamethasone in BFM Protocols for Children With Acute Lymphoblastic Leukemia Completed NCT00411541 Phase 4 vincristine;dexamethasone
39 Fludarabine, Cytarabine, Topotecan in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia Completed NCT00488709 Phase 4 Topotecan;Fludarabine;Cytarabine
40 Treatment of Acute Promyelocytic Leukemia With All-Trans Retinoic Acid (ATRA) and Idarubicin (AIDA) Completed NCT00465933 Phase 4 AIDA
41 Respiratory Viral Infections During Acute Myeloid Leukemia (AML)Chemotherapy Related Aplasia Completed NCT01819792 Phase 4
42 PROPHYSOME: Pilot Study on Safety of a Weekly Administration of 10mg/kg of AmBisome® in Antifungal Prophylaxis Treatment of Allogeneic Stem-cell Transplantation and Acute Leukaemia Completed NCT00362544 Phase 4 Ambisome
43 Glivec® (Imatinib Mesylate, STI571) in Monotherapy Versus Glivec®-Interferon Alpha in the Treatment of Chronic-Phase Chronic Myeloid Leukaemia Completed NCT00390897 Phase 4 Glivec;Interferon
44 Posaconazole Versus Micafungin for Prophylaxis Against Invasive Fungal Infections During Neutropenia in Patients Undergoing Chemotherapy for Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia or Myelodysplastic Syndrome Completed NCT01200355 Phase 4 micafungin;posaconazole
45 Rituximab Plus Chemotherapy for CD20+ Adult Acute Lymphoblastic Leukemia Completed NCT01358253 Phase 4 Cyclophosphamide;Doxorubicin;Vincristine;Dexamethasone;Cytarabine;Methotrexate;Rituximab;6-Mercaptopurine;Prednisone;L-asparaginase
46 Treatment of Newly Diagnosed Patients With Acute Promyelocytic Leukemia (PETHEMA LPA 2005) Completed NCT00408278 Phase 4 ATRA;Idarubicina;Mitoxantrone;ARA-C
47 Study of Oral AMN107 (Nilotinib) in Adult Patients With Imatinib - Resistant or - Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase Previously Enrolled to CAMN107A2109 Trial Completed NCT01368523 Phase 4 nilotinib
48 AML2003 - Standard-Therapy vs Intensified Therapy for Adult Acute Myeloid Leukemia Patients <= 60 Years Completed NCT00180102 Phase 4 Cytarabine vs. Cytarabine+Amsacrine+Mitoxantrone
49 Antiviral Treatment of Chronic Lymphocytic Leukemia Completed NCT01255644 Phase 4 Valganciclovir
50 PETHEMA LAL-RI/96: Treatment for Patients With Standard Risk Acute Lymphoblastic Leukemia Completed NCT00494897 Phase 4 Asparaginase;Cyclophosphamide;Cytarabine;Daunorubicin;Mercaptopurine;Prednisone;Vincristine;Methotrexate

Search NIH Clinical Center for Leukemia

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Leukemia cell therapies at LifeMap Discovery.

Cochrane evidence based reviews: leukemia

Genetic Tests for Leukemia

Genetic tests related to Leukemia:

# Genetic test Affiliating Genes
1 Leukemia 30

Anatomical Context for Leukemia

MalaCards organs/tissues related to Leukemia:

42
Myeloid, T Cells, B Cells, Bone, Bone Marrow, Monocytes, Breast

Publications for Leukemia

Articles related to Leukemia:

(show top 50) (show all 54344)
# Title Authors Year
1
The Ex Vivo Treatment of Donor T cells with Cosalane, an HIV Therapeutic and Small Molecule Antagonist of CC-Chemokine Receptor 7, Separates Acute Graft-versus-Host Disease from Graft-versus-Leukemia Responses in Murine Hematopoietic Stem Cell Transplant Models. ( 30668984 )
2019
2
Development of pre-engraftment syndrome, but not acute graft-versus-host disease, reduces relapse rate of acute myeloid leukemia after single cord blood transplantation. ( 30771495 )
2019
3
Very rare lineage switch from acute myeloid leukemia to mixed phenotype acute leukemia, B/Myeloid, during chemotherapy with no clonal evolution. ( 30707502 )
2019
4
Mouse acute leukemia develops independent of self-renewal and differentiation potentials in hematopoietic stem and progenitor cells. ( 30733302 )
2019
5
Long Non-Coding RNA and Acute Leukemia. ( 30744139 )
2019
6
Analytical performance of automated platelet counts and impact on platelet transfusion guidance in patients with acute leukemia. ( 30761915 )
2019
7
Concomitant use of blinatumomab and donor lymphocyte infusion for mixed-phenotype acute leukemia: a case report with literature review. ( 30786841 )
2019
8
'Acute leukemia in congenital methehemoglobinemia - an enigma to explore'. ( 30788079 )
2019
9
Sorafenib improves survival of FLT3-mutated acute myeloid leukemia in relapse after allogeneic stem cell transplantation: a report of EBMT acute leukemia Working Party. ( 30792203 )
2019
10
Doripenem versus meropenem as first-line empiric therapy of febrile neutropenia in patients with acute leukemia: a prospective, randomized study. ( 30824955 )
2019
11
Audit of Quality and Quantity of Nucleic Acid Yield from Pediatric Acute Leukemia Cases Following a Bio-banking Initiative. ( 30828152 )
2019
12
Mixed Phenotype Acute Leukemia, B/Myeloid with t(9;22): Diagnostic and Therapeutic Challenges. ( 30828170 )
2019
13
Psychosocial Experiences of Young Adults Diagnosed With Acute Leukemia During Hospitalization for Induction Chemotherapy Treatment. ( 30829935 )
2019
14
Correction to: Minimal residual disease- and graft-vs.-host disease-guided multiple consolidation chemotherapy and donor lymphocyte infusion prevent second acute leukemia relapse after allotransplant. ( 30836977 )
2019
15
Lipodystrophy-like features after total body irradiation among survivors of childhood acute leukemia. ( 30844749 )
2019
16
Spectrum and Immunophenotypic Profile of Acute Leukemia: A Tertiary Center Flow Cytometry Experience. ( 30858955 )
2019
17
ATP-Binding Cassette transporters' gene expression in pediatric patients with acute leukemia; a comprehensive analysis of published reports through PubMed search engine. ( 30860475 )
2019
18
Acute leukemia in a patient with 15q overgrowth syndrome. ( 30861314 )
2019
19
Identification of chromosomal abnormalities and genomic features in near-triploidy/tetraploidy-acute leukemia by fluorescence in situ hybridization. ( 30863166 )
2019
20
Checkpoint inhibition of PD-L1 and CTLA-4 in a child with refractory acute leukemia. ( 30863527 )
2019
21
High rates of ovarian function preservation after hematopoietic cell transplantation with melphalan-based reduced intensity conditioning for pediatric acute leukemia: an analysis from the Japan Association of Childhood Leukemia Study (JACLS). ( 30864117 )
2019
22
Mixed-phenotype acute leukemia with t(4;11)(q21;q23) KMT2A-AFF1-rearranged. ( 30872272 )
2019
23
Efficacy of levofloxacin as an antibacterial prophylaxis for acute leukemia patients receiving intensive chemotherapy: a systematic review and meta-analysis. ( 30880638 )
2019
24
Ophthalmic Manifestations of Acute Leukemia. ( 30891378 )
2019
25
Association between NAT2 polymorphisms and acute leukemia risk: A meta-analysis. ( 30896661 )
2019
26
Staging of acute leukemia based on central nervous system involvement alone: Is it appropriate? ( 30900807 )
2019
27
Nasal embryonal rhabdomyosarcoma with bone marrow metastasis simulating acute leukemia: A case report and review of the literature. ( 30902383 )
2019
28
Outcomes after Second Hematopoietic Cell Transplantation in Children and Young Adults with Relapsed Acute Leukemia. ( 30244103 )
2019
29
Peripheral blood flow cytometry for the diagnosis of pediatric acute leukemia: Highly reliable with rare exceptions. ( 30255571 )
2019
30
Initial Diagnostic Work-Up of Acute Leukemia: ASCO Clinical Practice Guideline Endorsement of the College of American Pathologists and American Society of Hematology Guideline. ( 30523709 )
2019
31
Clinically useful flow cytometry approach to identify immunophenotype in acute leukemia. ( 30614357 )
2019
32
Early Deaths in Pediatric Acute Leukemia: A Major Challenge in Developing Countries. ( 30615014 )
2019
33
Therapeutic granulocyte transfusions: neutropenic patients with acute leukemia continue to need them - why are definitive evidence-based practice guidelines elusive? ( 30615809 )
2019
34
Increased Health Care Utilization and Costs in Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia and Myelodysplastic Syndromes in Adolescents and Young Adults Compared with Children: A Multicenter Study. ( 30625391 )
2019
35
Challenges in Clinical Metaproteomics Highlighted by the Analysis of Acute Leukemia Patients with Gut Colonization by Multidrug-Resistant Enterobacteriaceae. ( 30626002 )
2019
36
Effect of laminar air flow and building construction on aspergillosis in acute leukemia patients: a retrospective cohort study. ( 30626352 )
2019
37
Impacts of thymoglobulin in patients with acute leukemia in remission undergoing allogeneic HSCT from different donors. ( 30626574 )
2019
38
Small molecule inhibitor of c-Myc 10058-F4 inhibits proliferation and induces apoptosis in acute leukemia cells, irrespective of PTEN status. ( 30639430 )
2019
39
Bloodstream infection (BSI) due to Vancomycin-Resistant Enterococcus (VRE) is associated with increased mortality after hematopoietic cell transplantation for acute leukemia and myelodysplastic syndrome: A multicenter, retrospective cohort study. ( 30649224 )
2019
40
Memantine potentiates cytarabine-induced cell death of acute leukemia correlating with inhibition of Kv1.3 potassium channels, AKT and ERK1/2 signaling. ( 30651113 )
2019
41
Resolution of celiac disease, IgA deficiency and platelet refractoriness after allogeneic bone marrow transplantation for acute leukemia. ( 30655374 )
2019
42
Mathematical models of amino acid panel for assisting diagnosis of children acute leukemia. ( 30674317 )
2019
43
Targeted Polo-like Kinase Inhibition Combined With Aurora Kinase Inhibition in Pediatric Acute Leukemia Cells. ( 30702467 )
2019
44
Maternal prenatal exposure to environmental factors and risk of childhood acute lymphocytic leukemia: A hospital-based case-control study in China. ( 30579239 )
2019
45
Novel EZH2 mutation in a patient with secondary B-cell acute lymphocytic leukemia after deletion 5q myelodysplastic syndrome treated with lenalidomide: A case report. ( 30608448 )
2019
46
FUSE binding protein 1 (FUBP1) expression is upregulated by T-cell acute lymphocytic leukemia protein 1 (TAL1) and required for efficient erythroid differentiation. ( 30653565 )
2019
47
PIM inhibitor SMI-4a induces cell apoptosis in B-cell acute lymphocytic leukemia cells via the HO-1-mediated JAK2/STAT3 pathway. ( 30658101 )
2019
48
Intractable anal pain in B-cell acute lymphocytic leukemia patients: treatment options. ( 30671206 )
2019
49
CD4+ cells as a potential biomarker for cytomegalovirus retinitis in children with acute lymphocytic leukemia. ( 30681505 )
2019
50
Allogeneic blood transfusion in 163 children with acute lymphocytic leukemia (a STROBE-compliant article). ( 30762790 )
2019